Draft monograph: CJC-1295 — disposition

§3Disposition and amendments

§3.1Disposition table

Table 1. Every submission with its disposition. Each row links to the submission in full.

§3.2Summary by disposition

Table 2. Counts by disposition, with the meaning of each.

§3.3Resulting amendments

1. The indication table mixes approved indications with uses for which the compound is merely supplied — arising from DRAFT-CJC-1295-MON/001. The indication table now carries a status column with three values, approved, under investigation and supplied without trial evidence, and the value is stated for every row. Rows in the third category also state that no certainty rating is assigned because…
2. Point estimates are given without an interval — arising from DRAFT-CJC-1295-MON/002. Every estimate now carries its interval where the source reported one, and where it did not, the estimate is annotated as reported without an interval rather than left to appear as a precise figure.
3. The monograph does not tell a reader that two vials of the same compound may not contain the same… — arising from DRAFT-CJC-1295-MON/003. A standing paragraph now appears at the head of §8 in every monograph, stating that a determination applies to the lot measured and that a label mass is not a determination.
4. What happens when the compound is stopped is not addressed — arising from DRAFT-CJC-1295-MON/004. Discontinuation trajectory is now an assessed outcome in every monograph where a contributing trial measured it, and a recorded evidence gap in every monograph where none did, so that its absence is visible rather than silent.
5. Registered trials that never reported are absent from the monograph — arising from DRAFT-CJC-1295-MON/005. The trial list now includes every registered trial the Institute identified, with its reporting status stated, and the monograph reports the proportion of registered trials for which no result has been posted or published.
6. The analytical section is longer than the clinical assessment it accompanies — arising from DRAFT-CJC-1295-MON/006. The analytical section is reduced to compound-specific content and cross-references the relevant standards for the general procedure, which shortens it substantially without removing what is not available elsewhere.
7. The analytical section assumes a reference standard that is not generally available — arising from DRAFT-CJC-1295-MON/007. The analytical section now states whether a reference standard is in general circulation for this compound and, where it is not, states which determinations remain possible and which become qualitative. A content figure obtained without a reference standard…
8. The preclinical section is extensive and the clinical section is not — arising from DRAFT-CJC-1295-MON/008. The preclinical section is reduced in length, placed after the clinical assessment rather than before it, and opens with a standing statement that an effect observed in an animal model is not a clinical outcome and does not support a certainty rating.
9. The compound is supplied under names the monograph does not list — arising from DRAFT-CJC-1295-MON/009. The synonym list is extended to include every name the Institute can evidence from a document it holds, each recorded with its source. Names asserted without a supporting document are not added, and the distinction is stated at the head of the list.
10. The recorded evidence gaps omit outcomes a reader would consider material — arising from DRAFT-CJC-1295-MON/011. The evidence-gap section is now derived from the anchor and decision-relevant outcomes for the indication, and any such outcome measured by no contributing trial is recorded as not measured rather than omitted.
11. The certainty rating for the principal assessed outcome cannot be traced to the contributing trials — arising from DRAFT-CJC-1295-MON/012. Each assessed outcome now carries its downgrade domains in the summary-of-findings row, with a short statement of the judgement made in each, so that the rating can be checked domain by domain against the contributing trials.
12. Anti-drug antibody data are omitted — arising from DRAFT-CJC-1295-MON/013. Anti-drug antibody incidence and any reported association with loss of effect are now reported where measured, and recorded as not measured where the contributing trials did not assess them.

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

1. International Organization for Standardization. ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories. ISO/IEC Standard 2017;3rd edition. identifier not held by the Institute

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.